Baseline clinical and pathological characteristics of patients treated with R-CHOP according to molecular subgroups defined by gene expression profile (DLBCL90)
| Characteristic of R-CHOP-treated patients . | DZsigpos . | GCB . | UNC . | ABC . | P . |
|---|---|---|---|---|---|
| Total (n) | 70 | 279 | 67 | 213 | |
| Age, median (range, y) | 64 (35-88) | 67 (22-92) | 64 (20-92) | 67 (31-93) | .18∗ |
| Age > 60 y (n, %) | 45 (64) | 181 (65) | 40 (60) | 143 (67) | .74 |
| Female sex (n, %) | 26 (37) | 122 (44) | 24 (36) | 102 (48) | .23 |
| Stage (n, %) | .01 | ||||
| I/II | 30 (43) | 151 (55) | 30 (46) | 85 (42) | |
| III/IV | 39 (57) | 120 (44) | 35 (54) | 119 (58) | |
| NA | 1 | 8 | 2 | 9 | |
| PS (n, %) | .29 | ||||
| 0-1 | 45 (65) | 190 (72) | 40 (65) | 128 (65) | |
| 2-4 | 24 (35) | 73 (28) | 22 (35) | 69 (35) | |
| NA | 1 | 16 | 5 | 16 | |
| LDH (n, %) | <.01 | ||||
| Normal | 24 (37) | 144 (61) | 37 (61) | 94 (53) | |
| Elevated | 40 (63) | 93 (39) | 24 (39) | 83 (47) | |
| NA | 6 | 42 | 6 | 36 | |
| Extranodal sites (n, %) | .47 | ||||
| 0-1 | 53 (77) | 221 (82) | 55 (85) | 158 (77) | |
| ≥ 2 | 16 (23) | 50 (18) | 10 (15) | 46 (23) | |
| NA | 1 | 12 | 2 | 9 | |
| B symptoms (n, %) | .34 | ||||
| No | 46 (67) | 197 (74) | 43 (66) | 136 (67) | |
| Yes | 23 (33) | 71 (26) | 22 (34) | 68 (33) | |
| NA | 1 | 7 | 2 | 9 | |
| Bulky disease ≥10 cm (n, %) | .34 | ||||
| No | 43 (67) | 186 (71) | 50 (79) | 146 (75) | |
| Yes | 21 (33) | 76 (29) | 13 (21) | 48 (24) | |
| NA | 6 | 17 | 4 | 19 | |
| IPI risk group (n, %) | .09 | ||||
| Low (0-1) | 20 (30) | 105 (44) | 22 (37) | 60 (33) | |
| Low-intermediate (2) | 16 (24) | 64 (27) | 16 (27) | 38 (21) | |
| High-intermediate (3) | 17 (26) | 42 (18) | 12 (20) | 42 (23) | |
| High (4, 5) | 13 (20) | 29 (12) | 10 (17) | 40 (22) | |
| Not calculable | 4 | 39 | 7 | 33 | |
| FISH-DH status, (n, %) | <.001 | ||||
| HGBCL-DH-BCL2 | 25 (38) | 9 (3) | 1 (2) | 1 (0.5) | |
| HGBCL-DH-BCL6 | 3 (5) | 1 (1) | 0 (0) | 4 (2) | |
| Atypical-DH† | 13 (20) | 57 (22) | 13 (20) | 42 (20) | |
| Non-DH | 25 (38) | 193 (74) | 51(78) | 159 (77) | |
| NA | 4 | 19 | 2 | 7 | |
| FISH total R, (n total/n data available, %)‡ | |||||
| Total MYC-R | 38/67 (57) | 15/262 (6) | 4/66 (6) | 16/207 (8) | <.001 |
| Total BCL2-R | 44/62 (71) | 81/221 (37) | 15/58 (26) | 3/178 (2) | <.001 |
| Total BCL6-R | 11/61 (18) | 43/213 (20) | 27/53 (51) | 55/167 (33) | <.001 |
| mRNA by digital GEP, mean log count (SD)‡ | |||||
| MYC | 11.9 (1.4) | 10.7 (0.81) | 10.8 (0.8) | 11.5 (0.9) | < .0001∗ |
| BCL2 | 12.4 (1.9) | 11.2 (1.6) | 11.7 (1.3) | 12.0 (1.3) | < .0001∗ |
| IHC, (n total/n data available, %)‡ | |||||
| MYC/BCL2 DPE | 32/58 (55) | 16/238 (7) | 12/57 (21) | 79/173 (46) | <.001 |
| MYC | 36/53 (68) | 37/215 (17) | 13/52 (25) | 85/165 (52) | <.001 |
| BCL2 | 53/66 (80) | 145/255 (57) | 52/64 (81) | 178/201 (89) | <.001 |
| BCL6 | 54/60 (90) | 216/235 (92) | 45/58 (78) | 108/165 (65) | <.001 |
| CD10 | 62/65 (95) | 161/243 (66) | 13/59 (22) | 9/179 (5) | <.001 |
| MUM1 | 2/56 (4) | 44/224 (20) | 28/53 (53) | 134/163 (82) | <.001 |
| GCB by Hans | 64/65 (99) | 207/232 (89) | 29/54 (54) | 23/159 (14) | <.001 |
| Characteristic of R-CHOP-treated patients . | DZsigpos . | GCB . | UNC . | ABC . | P . |
|---|---|---|---|---|---|
| Total (n) | 70 | 279 | 67 | 213 | |
| Age, median (range, y) | 64 (35-88) | 67 (22-92) | 64 (20-92) | 67 (31-93) | .18∗ |
| Age > 60 y (n, %) | 45 (64) | 181 (65) | 40 (60) | 143 (67) | .74 |
| Female sex (n, %) | 26 (37) | 122 (44) | 24 (36) | 102 (48) | .23 |
| Stage (n, %) | .01 | ||||
| I/II | 30 (43) | 151 (55) | 30 (46) | 85 (42) | |
| III/IV | 39 (57) | 120 (44) | 35 (54) | 119 (58) | |
| NA | 1 | 8 | 2 | 9 | |
| PS (n, %) | .29 | ||||
| 0-1 | 45 (65) | 190 (72) | 40 (65) | 128 (65) | |
| 2-4 | 24 (35) | 73 (28) | 22 (35) | 69 (35) | |
| NA | 1 | 16 | 5 | 16 | |
| LDH (n, %) | <.01 | ||||
| Normal | 24 (37) | 144 (61) | 37 (61) | 94 (53) | |
| Elevated | 40 (63) | 93 (39) | 24 (39) | 83 (47) | |
| NA | 6 | 42 | 6 | 36 | |
| Extranodal sites (n, %) | .47 | ||||
| 0-1 | 53 (77) | 221 (82) | 55 (85) | 158 (77) | |
| ≥ 2 | 16 (23) | 50 (18) | 10 (15) | 46 (23) | |
| NA | 1 | 12 | 2 | 9 | |
| B symptoms (n, %) | .34 | ||||
| No | 46 (67) | 197 (74) | 43 (66) | 136 (67) | |
| Yes | 23 (33) | 71 (26) | 22 (34) | 68 (33) | |
| NA | 1 | 7 | 2 | 9 | |
| Bulky disease ≥10 cm (n, %) | .34 | ||||
| No | 43 (67) | 186 (71) | 50 (79) | 146 (75) | |
| Yes | 21 (33) | 76 (29) | 13 (21) | 48 (24) | |
| NA | 6 | 17 | 4 | 19 | |
| IPI risk group (n, %) | .09 | ||||
| Low (0-1) | 20 (30) | 105 (44) | 22 (37) | 60 (33) | |
| Low-intermediate (2) | 16 (24) | 64 (27) | 16 (27) | 38 (21) | |
| High-intermediate (3) | 17 (26) | 42 (18) | 12 (20) | 42 (23) | |
| High (4, 5) | 13 (20) | 29 (12) | 10 (17) | 40 (22) | |
| Not calculable | 4 | 39 | 7 | 33 | |
| FISH-DH status, (n, %) | <.001 | ||||
| HGBCL-DH-BCL2 | 25 (38) | 9 (3) | 1 (2) | 1 (0.5) | |
| HGBCL-DH-BCL6 | 3 (5) | 1 (1) | 0 (0) | 4 (2) | |
| Atypical-DH† | 13 (20) | 57 (22) | 13 (20) | 42 (20) | |
| Non-DH | 25 (38) | 193 (74) | 51(78) | 159 (77) | |
| NA | 4 | 19 | 2 | 7 | |
| FISH total R, (n total/n data available, %)‡ | |||||
| Total MYC-R | 38/67 (57) | 15/262 (6) | 4/66 (6) | 16/207 (8) | <.001 |
| Total BCL2-R | 44/62 (71) | 81/221 (37) | 15/58 (26) | 3/178 (2) | <.001 |
| Total BCL6-R | 11/61 (18) | 43/213 (20) | 27/53 (51) | 55/167 (33) | <.001 |
| mRNA by digital GEP, mean log count (SD)‡ | |||||
| MYC | 11.9 (1.4) | 10.7 (0.81) | 10.8 (0.8) | 11.5 (0.9) | < .0001∗ |
| BCL2 | 12.4 (1.9) | 11.2 (1.6) | 11.7 (1.3) | 12.0 (1.3) | < .0001∗ |
| IHC, (n total/n data available, %)‡ | |||||
| MYC/BCL2 DPE | 32/58 (55) | 16/238 (7) | 12/57 (21) | 79/173 (46) | <.001 |
| MYC | 36/53 (68) | 37/215 (17) | 13/52 (25) | 85/165 (52) | <.001 |
| BCL2 | 53/66 (80) | 145/255 (57) | 52/64 (81) | 178/201 (89) | <.001 |
| BCL6 | 54/60 (90) | 216/235 (92) | 45/58 (78) | 108/165 (65) | <.001 |
| CD10 | 62/65 (95) | 161/243 (66) | 13/59 (22) | 9/179 (5) | <.001 |
| MUM1 | 2/56 (4) | 44/224 (20) | 28/53 (53) | 134/163 (82) | <.001 |
| GCB by Hans | 64/65 (99) | 207/232 (89) | 29/54 (54) | 23/159 (14) | <.001 |
P values derived from Fisher exact test unless otherwise stated. P < .05 have been highlighted in bold.
DH, double-hit; DPE, dual protein expressor; DZsigpos, DZsig positive; GCB, germinal B-cell-like; IPI, international prognostic index; LDH, lactate dehydrogenase; mRNA, messenger RNA; MYC-R, MYC-rearrangement; NA, not available; PS, performance status; R, rearrangement; SD, standard deviation; UNC, unclassified COO.
Multifactor analysis of variance.
Atypical-DH lymphoma as defined in supplemental Figure 11A.
Each row represents a unique variable compared separately.